Core evidence clinical impact summary for etanercept in psoriasis

Outcome measure	Evidence	Implications
Patient-oriented evidence
Severity and clearance of disease	Clear	Etanercept reduces disease severity and improves clearance rates compared with placebo
Delay of relapse	Clear	Relapse occurs after a mean of 3 months from cessation of active treatment, with relapse >4.5 months in 20% of patients
Quality of life	Clear	Etanercept improves quality of life measures more than placebo
Tolerability	Substantial	Injection site reactions are more common with etanercept compared with placebo. Screening procedures and guidelines should be used when considering patients for treatment in order to reduce the risk of serious infection and to monitor the potential risk of malignancy
Economic evidence
Cost effectiveness	Moderate	Etanercept 25 mg twice weekly is cost effective in patients with severe disease who are not suitable for systemic therapy